Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus TARPEYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus TARPEYO.
FLUDROCORTISONE ACETATE vs TARPEYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
TARPEYO (budesonide) is a corticosteroid with anti-inflammatory activity. It acts by binding to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and immune cell activation, thereby reducing proteinuria in IgA nephropathy.
0.1 mg orally once daily, range 0.05-0.2 mg/day
16 mg/kg intravenously once daily on Days 1-5 of each 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life is approximately 27.3 hours (range 21-36 hours) in patients with IgA nephropathy. This supports once-weekly subcutaneous dosing without dose adjustment over the dosing interval.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Primarily hepatic metabolism, with <1% excreted unchanged in urine and <1% in feces. Elimination is predominantly via biliary excretion of metabolites into feces, accounting for >90% of total clearance.
Category D/X
Category C
Corticosteroid
Corticosteroid